Trial Profile
A New Modified-Release Tablet Formulation of Prednisone (Lodotra) in Patients With Nocturnal Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Prednisone (Primary)
- Indications Nocturnal asthma
- Focus Therapeutic Use
- Acronyms MONA
- Sponsors Horizon Pharma AG
- 04 Jul 2012 Planned number of patients changed from 10 to 30 as reported by European Clinical Trials Database.
- 15 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Mar 2011 Actual end date (May 2010) added as reported by ClinicalTrials.gov.